Elicio Therapeutics, Inc. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings
Elicio Therapeutics, Inc. (ELTX) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings of $13.98 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-30.
Discontinued › Income Statement › Other Income
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings · last filed 2022-03-30
- Elicio Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2021-12-31 was -$272.00K.
- Elicio Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2021-09-30 was -$128.00K.
- Elicio Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2021-06-30 was -$200.00K.
- Elicio Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for the quarter ending 2021-03-31 was $14.58M.
- Elicio Therapeutics, Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, gain (loss) included in earnings for fiscal 2021 was $13.98M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings 12 month |
|---|---|---|---|---|
| 2021-12-31 | -$272.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | -$400.00K derived: sum of 2 quarters · filed 2022-03-30 | -$600.00K derived: sum of 3 quarters · filed 2022-03-30 | $13.98M 10-K · filed 2022-03-30 |
| 2021-09-30 | -$128.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | -$328.00K derived: sum of 2 quarters · filed 2021-11-12 | $14.25M 10-Q · filed 2021-11-12 | |
| 2021-06-30 | -$200.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $14.38M 10-Q · filed 2021-08-12 | ||
| 2021-03-31 | $14.58M 10-Q · filed 2021-05-17 | |||
| 2020-12-31 | $16.53M 10-Q · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |